Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2011 Jun;15(6):754-60. doi: 10.5588/ijtld.10.0568.

Treatment interruptions and inconsistent supply of anti-tuberculosis drugs in the United Kingdom.

Author information

1
Pharmacy Department, St James's University Hospital, Leeds, UK. Toby.Capstick@leedsth.nhs.uk

Abstract

SETTING:

National Health Service (NHS) centres treating tuberculosis (TB) in the United Kingdom.

OBJECTIVES:

To describe NHS TB treatment centres' experience of obtaining anti-tuberculosis drugs to treat drug-susceptible and drug-resistant TB between 2007 and 2009. In particular: 1) any difficulties experienced in obtaining different drugs; 2) resulting interruptions or alterations in the prescribed regimen; 3) availability of paediatric formulations; and 4) resources available to identify and manage drug shortages.

DESIGN:

Questionnaires were sent to pharmacists at 168 treatment centres.

RESULTS:

Of the 77 (46%) treatment centres that responded, 63% (48/77) reported difficulties in obtaining anti-tuberculosis drugs. Consequently, 27% had to interrupt the prescribed treatment regimen at least once, whilst 19% had to alter the regimen. Of 55 centres treating multidrug-resistant tuberculosis, 36% reported difficulties obtaining second-line drugs, 16% had to interrupt the prescribed treatment regimen at least once and 5% had to alter the regimen. A lack of licensed liquid formulations for children resulted in 26% of treatment centres using unlicensed, variable-strength liquids and locally prepared suspensions.

CONCLUSIONS:

Difficulties obtaining drugs to treat both drug-susceptible and drug-resistant disease are common in the UK. There are particular risks for children. Our data identify an urgent need for national strategic guidance to ensure a consistent and reliable supply of anti-tuberculosis drugs.

PMID:
21575294
DOI:
10.5588/ijtld.10.0568
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center